Agilent Technologies' new 1200 Infinity Liquid Chromatography Series offers more productivity, confidence, and affordability

Agilent Technologies' new 1200 Infinity Series, sets new levels of performance in analytical HPLC and UHPLC. The 1200 Infinity Series includes the new Agilent 1220 Infinity LC, the new Agilent 1260 Infinity LC and the enhanced Agilent 1290 Infinity LC. The Agilent 1200 Infinity Series  marks the evolution of the successful 1200 Series LC family and 1120 Compact LCs using latest 1200 Series Rapid Resolution LC and 1290 Infinity LC technologies.

The 1200 Infinity Series portfolio offers a seamless integration of column technology, instrumentation and software to ensure utmost productivity. The 1220 and 1260 Infinity LCs offer enhanced HPLC and RRLC performance at an HPLC price. All 1220 and 1260 Infinity systems are standardized on 600 bar system pressure, 80 Hz data-acquisition speed and 2x or 10x higher UV sensitivity. The 1220 and 1260 Infinity LCs are 100 percent compatible with HPLC methods, ensuring risk-free replacement or upgrades of existing 1100 or 1200 Series instruments. Further, the new 1260 Infinity Quaternary Bio-inert LC system offers the highest performance in bio-analysis and bio-purification.

"We ended the UHPLC debate with last year's introduction of the Agilent 1290 Infinity LC," said Patrick Kaltenbach, Agilent's vice president and general manager, Liquid Phase Separations Business. "Now we are raising the HPLC standard with a new portfolio that offers a unique continuum of future-proof HPLC, RRLC and UHPLC solutions to match any application or budget."

The Agilent 1200 Infinity Series portfolio allows customers to tailor the exact systems they need, from the simplest manual isocratic LC through the world's highest-performance, fastest, most sensitive UHPLC systems. The power range of 1200 Infinity Series LC systems is fully compatible with the latest column technology, such as 600 bar Poroshell and Zorbax RRHT or 1200 bar Zorbax RRHD columns. 

Agilent 1220 Infinity LC -- Infinitely More Affordable
The 1220 Infinity LC is an integrated and easy-to-use system for routine HPLC and advanced RRLC analyses, providing maximum return on investment. The 1220 Infinity LC offers a 600 bar power range at up to 5 mL/min and up to 10 mL/min at lower pressure, an 80 Hz detector speed and is fully compatible with all additional detectors within the 1200 Infinity Series, as well as with Agilent 6100 Series Single Quadrupole LC/MS Systems. Besides being capable of running RRLC applications, the 1220 Infinity can run existing conventional HPLC methods. The 1220 Infinity LC offers superior Agilent quality and utilizes 1260 or even 1290 Infinity LC technology and parts.

Agilent 1260 Infinity LC -- Infinitely More Confident
The 1260 Infinity LC offers more rapid resolution power, pushing RRLC performance to new limits. The power range of the 1260 Infinity Isocratic and Quaternary Pump of 600 bar at 5 mL/min and up to 10 mL/min at lower pressure easily handles 3.0 and 4.6 mm id columns with sub-2-micron or superficially porous particles used in new Poroshell columns. The 1260 Infinity Binary LC uses high-pressure solvent mixing for superior gradient accuracy at 600 bar and up to 5 mL/min and allows lower delay volumes, making it well suited for narrow bore columns.

Further, the new 1260 Infinity Diode Array Detector increases UV sensitivity by 10-fold allowing more accurate peak detection and integration.

Full HPLC and RRLC compatibility enables unchanged execution of existing methods while being prepared for a seamless transfer to modern columns technologies whenever required. The 1260 Infinity Quaternary LC is also available as a 100 percent bio-inert version with widest, 1-14 pH-range. All 1260 Infinity LC systems are priced similarly to earlier 1200 Series HPLC systems.

Agilent 1290 Infinity LC - Infinitely More Powerful
The 1290 Infinity LC delivers the industry's highest performance -- speed, resolution, sensitivity, accuracy and precision. Enabling system features are a power range up to 1200 bar pressure, flow rates up to 5 mL/min, 10x-UV-sensitivity at 160 Hz detection speed and carry-over performance of typically less than10 ppm with the newly released 1290 Infinity Flexible Cube.  The 1290 Infinity LC enables users to deploy any particle type, any column dimensions or any mobile and stationary phases. Further, it is the only system that offers highest UHPLC productivity at HPLC service costs and also the first to deliver the foundation for method transferability to and from any vendor's UHPLC and HPLC systems.

The 1260 and 1290 Infinity LCs are fully compatible with all Agilent 6000 Series high-end mass detectors.

For further information, view website: www.agilent.com   Refer to page 242

Agilent Technologies' new Bio-Inert LC is designed to
characterize large biomolecules, new biological entities

Agilent Technologies' new 1260 Infinity bio-inert quaternary liquid chromatography (LC) system is designed to characterize and confirm large biomolecules, especially new biological entities (NBEs) and therapeutic monoclonal antibodies.

"This new system is a complete solution for addressing the growing demand to analyze NBEs and biosimilars, as drug developers seek to determine safety and efficacy of these complex molecules," said Stefan Schuette, Agilent LC marketing director. "There are huge benefits to increasing robustness and performance significantly for large biomolecule analysis, increasing productivity, uptime and reproducibility. We think users will agree that this new system succeeds."

The system is based on the new Agilent 1260 Infinity LC system with quaternary pump module. It features a completely inert, metal-free sample-flow path, and a stainless steel-free solvent delivery path to protect sample integrity and to minimize unspecific surface interaction and corrosion of the instrument. The system tolerates a very wide pH range from 1 to as high as 14. Agilent also offers a family of BioHPLC ion exchange and size exclusion columns designed for these specific types of analyses, contributing to the robust, reproducible high-resolution performance.

The standard detector and the 600-bar power range combine to provide the lowest detection limits and highest resolution per time for any bio-inert LC-based bioseparation system, from low-pressure methods up through small-particle, high-pressure column technology.

The new Agilent bio-inert LC system can accommodate both bioanalysis and bio-purification tasks, offering analytical flow rates and fraction collection as high as 10 ml/min.

For further information, view website: www.agilent.com   Refer to page 244

New state-of-the-art radiochemistry facility fully operational

Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, today announced that its new, state-of-the-art radiochemistry facility in Cardiff, UK is fully operational and that shipments of radiolabelled products have commenced.

All staff have successfully transferred from the former site operated by Amersham Radiolabelling Services to the new facility.

The new facility, located close to Cardiff Bay, represents a significant investment by Quotient and follows the Company's acquisition of Amersham Radiolabelling Services from GE Healthcare in June 2009. The facility has been named "The Old Glassworks", reflecting the origins of the site on which it was built.

The Old Glassworks will produce radiolabelled compounds for its pharmaceutical, biotechnology and agrochemical clients, offering an established bespoke service for the custom synthesis of carbon-14 and tritium labelled compounds. Quotient's capabilities allow it to manufacture custom radiolabelled drugs for use in both pre-clinical and clinical settings.

Quotient offers its clients a unique range of services with world-leadership positions in a number of key disciplines, including custom radiosynthesis services and carbon-14-enabled drug development. With its strong existing client base in Europe, the United States and Japan, Quotient will serve over 250 clients worldwide from The Old Glassworks.  Its chemists work closely with the company's metabolism and clinical research groups to deliver clients the most effective solution for their carbon-14 enabled drug development needs, reducing complexity, cost and timelines.

The Old Glassworks has been equipped with world-class technology, operating to the highest environmental and safety standards. It houses the largest and most experienced team of radiosynthesis chemists in the world and brings the total number of Quotient employees to over 600.

Paul Cowan, Chairman & Chief Executive Officer, Quotient, said, "With the opening of the new Cardiff facility, we have made a significant investment to support the product development needs of our pharmaceutical, biotechnology and agrochemicals clients. We have invested significantly in technology that will make the business operate sustainably and allow our expert chemists to efficiently deliver the highest quality products to our clients. With almost one-third of all registered drugs on the market today having been radiolabelled by Quotient chemists, the opening of The Old Glassworks will allow us to continue to expand on this record of success."

Stephen Lewinton, Managing Director, Quotient Chemistry and Metabolism, said: "The new facility demonstrates our commitment to the radiochemicals business and allows us to build on our fully integrated carbon-14-enabled drug development services (including Synthesis-to-Clinic). Quotient remains focused on meeting the needs of its clients for cost-effective custom radiosynthesis services."

The last of the chemists transferred to The Old Glassworks as scheduled in early May, as planned. After rigorous safety and emissions testing, The Old Glassworks is now fully operational and the first products have been shipped. An official opening ceremony will be held in September 2010.

Quotient Bioresearch in profile
Quotient is a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide. The company offers a unique range of drug development services through its three key focus areas - Chemistry & Metabolism, Bioanalytical Sciences and Clinical Services. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch is part of Quotient Bioresearch Group, which comprises Quotient Bioresearch and HFL Sport Science.

For further information, e-mail: info.amersham@quotientbioresearch.com or view website: www.quotientbioresearch.com  Refer to page 292

SAW Instruments announces
North American launch of sam®X

SAW Instruments, developer of the innovative sam® family of biosensors for real-time, label-free assays using living cells, will launch its new sam®X biosensor in North America at the IBC's Antibody Engineering and Antibody Therapeutics (AEAT) meeting in San Diego, CA, USA (4-8 December 2011). As part of the launch, SAW will be exhibiting the sam®X at booth #212 and will also present a poster, entitled "Binding Kinetics of Therapeutic Antibodies to Native Proteins on Living Cells". The high-end sam®X provides several innovative features that further optimise the system for a mammalian cell-based binding assay workflow. These include an expansion in the number of sensor chips to two, increasing the channels available to 8. Each can be addressed by the fluidics individually or in combinations, a factor that also facilitates on-chip immobilisation at each sensor position. The system can be used with unfixed cells in suspension, which are injected afresh for each measurement, or adherent cells grown directly on the sensor chips themselves. Most importantly, assays are completed in mere minutes, enabling accurate real-time kinetics data to be captured.

The system can be used with unfixed cells in suspension, which are injected afresh for each measurement, or adherent cells grown directly on the sensor chips themselves.

For further information on the sam® family of biosensors, including the new sam®X, book a personal demonstration at AEAT 2011 in advance by visiting the contact page of the SAW website or by calling the company's US sales number (toll free) on 1-866-459-2774.

Also, for a limited time only, the sam®X will be available at a special offer introductory price. Visit the SAW Instruments booth to request full details

For further information, view website: www.saw-instruments.de  Refer to page 288